High materiality7/10
Viridian Therapeutics price target raised to $36 from $35 at RBC Capital
Why it may matterVerify against the original reporting
RBC upgrade implies positive re-rating for VRDN.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
RBC Capital raises VRDN target to $36; current price at signal time $22.76; priceChangeSinceSignal +3.65 indicates upside potential.
- Target to $36
- Current price $22.76
- Upside potential
Key facts
- 01
Target: $36
- 02
Posted price: $22.76
- 03
Analyst firm: RBC Capital
- 04
Analyst: Lisa Walter
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.